Search
+
    SEARCHED FOR:

    BALANCED SCHEMES

    Gokaldas Exports MD on PLI scheme, export growth and organic growth expected in ‘24

    Gokaldas Exports focuses on women's fashion, outerwear, and sportswear. They will continue to focus on those segments and are seeing growth across all of these product categories.A 15% growth should be possible organically, that is how the company management is looking at the business unfolding over the next two to three years.

    Sensex at 80K: A simple ETF or index fund SIP of Rs 10,000 would have made you a crorepati in 2 decades

    Rs 10,000 SIP in ICICI Prudential BSE Sensex ETF: Rs 1.55 crore (XIRR 14.62%). HDFC Index Fund-BSE Sensex: Rs 1.47 crore (XIRR 13.70%). Tata BSE Sensex Index Fund: Rs 1.28 crore (XIRR 13.25%). LIC MF BSE Sensex Index Fund: Rs 1.20 crore. Axis BSE Sensex Index Fund (Feb 2024) offers XIRR 52.70%. Sensex hits 80k. Ashish Kumar advises caution.

    Quant Mutual Fund crisis is another lesson in diversification. Here's why

    ​Diversification in the investment world is not limited to spreading your bets across asset classes and stocks but Sebi's investigation against Quant Mutual Fund in a front-running case is also a reminder of concentration risk in owning mutual funds from just one asset management company.

    Quant Mutual Fund crisis: How NAVs have been impacted since Sebi investigation

    Investor concerns arise as front-running case impacts Quant Mutual Fund. Despite NAV declines in Quant Healthcare Fund and Quant Commodities Fund, stability is maintained with rising NAVs of Quant ESG Equity Fund and Quant Focused Fund.

    Indian companies have made a comeback. Will MNCs be able to do it ? 7 MNC pharma stocks with upside potential of up to 21%

    While they still trade at premium valuations, they have not created wealth for shareholders. The fact is an age-old theory that just having a MNC stock in your portfolio is an assurance of growth and return no longer holds true. There was a time when having MNC stock, irrespective of the sector it was from, was a must have in one's portfolio. The reason: liberal at giving bonuses, dividend payments were good and given the fact some of them actually owned the best of the brands which had seen a secular growth due to which they were also able to deliver decent returns to shareholders. But after the IT bull of 2000, as a new set of Indian companies took the centerstage, a number of MNCs stocks lost their shine at least on the street. In the last few years, a number of pharma companies have been putting their house in order, either due to global merger and selling a part of Indian business to focus more on core products.

    More than 50% value and contra mutual funds outperform benchmarks. Should you invest?

    Around 69% and 100% of value and contra mutual funds respectively outperformed benchmarks in the last three years, driven by market recovery and strategic stock selection, as per ETMutualFunds and experts like Abhishek Jain from Arihant Capital.

    The Economic Times
    BACK TO TOP